Showing 3681-3690 of 8095 results for "".
Evaluating Hyaluronic Acids in Patients with Skin of Color
https://practicaldermatology.com/topics/general-topics/1109_05-php/22057/One expert places new findings in perspective and explains why new data on fillers in skin of color are essential.Rising Skin Cancer Rates are a Global Reality
https://practicaldermatology.com/topics/general-topics/PD1009_04-php/20367/One group of researchers questions the skin cancer epidemic, but the overwhelming evidence suggests that rates are rising.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0909_05-php/22769/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0809_06-php/22785/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0709_04-php/22799/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0509_05-php/22827/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0309_06-php/22860/You Want to Start A New Practice: Now What?
https://practicaldermatology.com/topics/general-topics/PD0309_12-php/22866/After making the decision to start a practice, constructing a solid business plan and financial overview is critical.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0209_05-php/22877/- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w